Trial Profile
A Phase 2 Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas Harboring H3.3 or H3.1 K27M Mutation
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Panobinostat (Primary)
- Indications Diffuse intrinsic pontine glioma; Glioma
- Focus Therapeutic Use
- 14 Aug 2019 Planned initiation date changed from 1 Jun 2019 to 1 Oct 2019.
- 14 Aug 2019 Status changed from recruiting to withdrawn prior to enrolment.
- 02 Aug 2019 Planned End Date changed from 1 Sep 2025 to 1 Oct 2025.